Dilated Cardiomyopathy Clinical Trial
Official title:
Effects of Respiratory Muscles Training on Cardiopulmonary Parameters and Quality of Life in Patients With Dilated Cardiomyopathy
Verified date | March 2020 |
Source | Riphah International University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study was to determine the effects of respiratory muscles training on
cardiopulmonary parameters and quality of life in patients with dilated cardiomyopathy (DCM).
It was a randomized control trial conducted on the calculated sample size of 22 patients
divided into 2 groups. Study was conducted at Shifa International Hospital Islamabad.
Clinically stable, diagnosed cases of DCM aged 30 to 60 years were included in the study.
Outcomes of study were ejection fraction, Left ventricular (LV) End systolic dimensions, LV
End diastolic dimension, lung volumes and capacities and quality of life. Data was analyzed
on Statistical Package for the Social Sciences (SPSS) version 21.
.
Status | Completed |
Enrollment | 22 |
Est. completion date | January 30, 2020 |
Est. primary completion date | January 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Diagnosed cases of DCM - New York Heart Association class (II) - Clinically stable patients for at least (3) months - Ejection Fraction (25 - 40%) Exclusion Criteria: - Recent myocardial infarction, exercise induced angina and Syncope, - Atrioventricular valve disease, selected for heart transplant - Uncontrolled hypertension. - Uncontrolled diabetes. - Significant pulmonary disease. Intellectual, neurological or musculoskeletal abnormalities. |
Country | Name | City | State |
---|---|---|---|
Pakistan | Riphah International University | Islamabad | Federal |
Lead Sponsor | Collaborator |
---|---|
Riphah International University |
Pakistan,
Drozdz T, Bilo G, Debicka-Dabrowska D, Klocek M, Malfatto G, Kielbasa G, Styczkiewicz K, Bednarek A, Czarnecka D, Parati G, Kawecka-Jaszcz K. Blood pressure changes in patients with chronic heart failure undergoing slow breathing training. Blood Press. 2016;25(1):4-10. doi: 10.3109/08037051.2016.1099800. Epub 2015 Oct 29. — View Citation
Gomes-Neto M, Durães AR, Conceição LSR, Roever L, Silva CM, Alves IGN, Ellingsen Ø, Carvalho VO. Effect of combined aerobic and resistance training on peak oxygen consumption, muscle strength and health-related quality of life in patients with heart failure with reduced left ventricular ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2019 Oct 15;293:165-175. doi: 10.1016/j.ijcard.2019.02.050. Epub 2019 Jun 24. — View Citation
Lachowska K, Bellwon J, Morys J, Gruchala M, Hering D. Slow breathing improves cardiovascular reactivity to mental stress and health-related quality of life in heart failure patients with reduced ejection fraction. Cardiol J. 2019 Jan 30. doi: 10.5603/CJ.a2019.0002. [Epub ahead of print] — View Citation
Leggio M, Fusco A, Loreti C, Limongelli G, Bendini MG, Mazza A, Coraci D, Padua L. Effects of exercise training in heart failure with preserved ejection fraction: an updated systematic literature review. Heart Fail Rev. 2019 Aug 9. doi: 10.1007/s10741-019-09841-x. [Epub ahead of print] Review. — View Citation
Neto MG, Martinez BP, Conceição CS, Silva PE, Carvalho VO. Combined Exercise and Inspiratory Muscle Training in Patients With Heart Failure: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 2016 Nov/Dec;36(6):395-401. Review. — View Citation
Russo MA, Santarelli DM, O'Rourke D. The physiological effects of slow breathing in the healthy human. Breathe (Sheff). 2017 Dec;13(4):298-309. doi: 10.1183/20734735.009817. — View Citation
Wasserstrum Y, Barbarova I, Lotan D, Kuperstein R, Shechter M, Freimark D, Segal G, Klempfner R, Arad M. Efficacy and safety of exercise rehabilitation in patients with hypertrophic cardiomyopathy. J Cardiol. 2019 Nov;74(5):466-472. doi: 10.1016/j.jjcc.2019.04.013. Epub 2019 Jun 22. — View Citation
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. doi: 10.1038/nrcardio.2016.25. Epub 2016 Mar 3. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ejection fraction | Ejection fraction calculated through echocardiography | After 4 weeks of intervention | |
Primary | LV End systolic dimension | LV End systolic dimension calculated through echocardiography | After 4 weeks of intervention | |
Primary | LV End diastolic dimension | LV End diastolic dimension calculated through echocardiography | After 4 weeks of intervention | |
Secondary | Memorial symptom assessment scale - Heart failure | Memorial symptom assessment scale for heart failure patients (MSAS-HF) is a patient-rated instrument to assess the quality of life of heart failure patients. It scores 32 symptoms including 26 physical symptoms of distress and 6 psychological symptoms are recorded. Distress is rated on a 5 point scale each symptom is scored from 0 to 4 ranging from "no symptom" to "very much." If the symptom is not present, a value of zero is assigned. Frequency of psychological symptoms is scored as 1-rarely, 2- occasionally, 3-frequently, and 4- almost constantly. The symptom scores are combined into various sub-scales scores including the psychological sub-scale score, physical sub-scale, global distress index and total MSAS score. The mean score in each category is calculated with higher scores indicating poor quality of life. |
After 4 weeks of intervention | |
Secondary | Forced Expiratory volume 1(FEV1) | Forced Expiratory volume 1(FEV1) measured through digital spirometer. If the value of FEV1 is within 80% of the reference value, the results are considered normal. | After 4 weeks of intervention | |
Secondary | Forced Vital capacity(FVC) | Forced Vital capacity(FVC) measured through digital spirometer. If the value of FVC is within 80% of the reference value, the results are considered normal. | After 4 weeks of intervention | |
Secondary | FEV1/FVC | FEV1/FVC measured through digital spirometer. The normal value for the FEV1/FVC ratio is 70% (and 65% in persons older than age 65). | After 4 weeks of intervention | |
Secondary | Peak Expiratory Flow Rate (PEFR) | Peak Expiratory Flow Rate (PEFR) measured through digital spirometer. Three zones of measurement are commonly used to interpret peak flow rates. Normal value of PEFR is (80-100%). Green zone indicates 80 to 100 percent of the usual or normal peak flow reading, yellow zone indicates 50 to 79 percent of the usual or normal peak flow readings, and red zone indicates less than 50 percent of the usual or normal peak flow readings. | After 4 weeks of intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|
||
Recruiting |
NCT04982081 -
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
|
Phase 1 | |
Not yet recruiting |
NCT04703751 -
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents
|
N/A | |
Recruiting |
NCT01157299 -
Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO
|
N/A | |
Completed |
NCT00765518 -
Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
|
Phase 2 | |
Completed |
NCT02115581 -
Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
|
Phase 4 | |
Recruiting |
NCT04246450 -
Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT05799833 -
Low QRS Voltages in Young Healthy Individuals and Athletes
|
||
Recruiting |
NCT01914081 -
Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
|
Phase 3 | |
Recruiting |
NCT02915718 -
A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT03893760 -
Assessment of Right Ventricular Function in Advanced Heart Failure
|
||
Not yet recruiting |
NCT01219452 -
Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02175836 -
Arrhythmia Prediction Trial
|
N/A | |
Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
Recruiting |
NCT05026112 -
The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
|
||
Recruiting |
NCT05237323 -
Micophenolate Mofetil Versus Azathioprine in Myocarditis
|
Phase 3 | |
Recruiting |
NCT04649034 -
Intraventricular Stasis In Cardiovascular Disease
|
||
Suspended |
NCT03071653 -
Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
|
Phase 2 | |
Completed |
NCT02619825 -
Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)
|
N/A |